1. Commitment to the discovery of novel therapeutic drugs
Regarding an oral antiviral drug (development number: S-217622) that selectively inhibits 3CL protease, enrolment has been completed in the Phase 2a Part of Phase 2/3 clinical trial? and Phase 2b/3 Part is currently underway.
2. Commitment to vaccine development
Regarding a preventive vaccine (development number: S-268019), of the four final stage clinical trials, Phase 2/3 clinical trial and an additional dose clinical trial are currently being conducted in
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Our efforts against COVID-19 are updated on our website as needed. A considerable amount of valuable information on COVID-19 from other websites is also summarized on this page, so please use it for reference:
Contact:
Website: https://www.shionogi.com/global/en/contact.html
(C) 2022 Electronic News Publishing, source